Frontiers in Immunology
Cure8 research brief
Why This Matters
FMT and precision microbiota therapies target the gut ecosystem, a modifiable factor in UC. For people with UC, this review explains potential mechanisms, where FMT has shown benefit in trials, and why it is still investigational for routine care.
Who Should Pay Attention
Patients with ulcerative colitis, clinicians treating UC, researchers in microbiome and immunology, and people interested in microbiota‑based therapies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This Frontiers in Immunology review summarizes how fecal microbiota transplantation (FMT) is thought to work in ulcerative colitis (UC) and what clinical trials so far show.
The authors describe multiple mucosal mechanisms — changes in microbial community structure, enrichment of short‑chain fatty acid producers, modulation of bile acid and tryptophan–aryl hydrocarbon signaling, improved epithelial barrier integrity, and effects on mucosal immunity (Th17/Treg balance, IgA responses, macrophage reprogramming, IL‑10/IL‑22 signaling, and neutrophil extracellular traps).
The review notes randomized controlled trials showing that FMT can induce clinical and endoscopic remission in selected UC patients, especially with lower‑GI delivery and multi‑donor or optimized regimens, but current guidelines do not support routine FMT outside clinical trials because of heterogeneity and low certainty of evidence.
Efficacy appears limited in moderate‑to‑severe or biologic‑refractory disease. The authors highlight precision approaches — donor–recipient functional matching, dietary modulation, combination therapy, and next‑generation microbiota therapeutics — as promising directions that need prospective validation.
Keep In Mind
This is a journal review (Frontiers in Immunology) summarizing mechanistic and trial evidence; it does not report new primary trial results. Current clinical guidelines do not recommend routine FMT outside trials due to heterogeneity and low certainty of evidence.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFrontiers in Immunology
PublisherFrontiers Media SA
AuthorsEnhui Lu, Miao Zhang, Yuanyang Zhao +2 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 20, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Microplastics, Gut Dysbiosis, and Inflammatory Pathways in Ulcerative Colitis.
If environmental microplastics contribute to gut dysbiosis and mucosal inflammation, this could help explain environmental triggers of ulcerative colitis and point toward prevention or microbiome-targeted interventions.
Macrophage-driven inflammation in inflammatory bowel disease: mechanisms and therapeutic opportunities
Macrophages and innate immune signaling are central to how gut inflammation starts and persists in IBD; better understanding these pathways could point to new treatment strategies for people whose disease doesn’t fully...
Gut microbiota dysbiosis in the pathogenesis of ulcerative colitis and the therapeutic efficacy of fecal microbiota transplantation: a meta-analysis
This study synthesizes randomized trial evidence about the role of gut microbiota in ulcerative colitis and whether fecal microbiota transplantation (FMT) can help induce remission. People with UC may encounter FMT as a...